Abstract:Introduction: Subcritical epileptiform activity is associated with impaired cognitive function and is commonly seen in patients with Alzheimer's disease (AD). The anti-convulsant, levetiracetam (LEV), is currently being evaluated in clinical trials for its ability to reduce epileptiform activity and improve cognitive function in AD. The purpose of the current study was to apply pharmacokinetics (PK), network analysis of medical imaging, gene transcriptomics, and PK/PD modeling to a cohort of amyloidogenic mice to establish how LEV restores or drives alterations in the brain networks of mice in a dose-dependent basis using the rigorous preclinical pipeline of the MODEL-AD Preclinical Testing Core. Methods: Chronic LEV was administered to 5XFAD mice of both sexes for 3 months based on allometrically scaled clinical dose levels from PK models. Data collection and analysis consisted of a multi-modal approach utilizing 18 F-FDG PET/MRI imaging and analysis, transcriptomic analyses, and PK/PD modeling. Results: Pharmacokinetics of LEV showed a sex and dose dependence in C max , CL/F, and AUC 0-∞ , with simulations used to estimate dose regimens. Chronic dosing at 10, 30, and 56 mg/kg, showed 18 F-FDG specific regional differences in brain uptake, and in whole brain covariance measures such as clustering coefficient, degree, network density, and connection strength (i.e., positive and negative). In addition, transcriptomic analysis via nanoString showed dose-dependent changes in gene expression in pathways consistent 18 F-FDG uptake and network changes, and PK/PD modeling showed a concentration dependence for key genes, but not for network covariance modeling. Discussion: This study represents the first report detailing the relationships of metabolic covariance and transcriptomic network changes resulting from LEV administration in 5XFAD mice. Overall, our results highlight non-linear kinetics based on dose and sex, where gene expression analysis demonstrated LEV dose- and concentration-dependent changes, along with cerebral metabolism, and/or cerebral homeostatic mechanisms relevant to human AD, which aligned closely with network covariance analysis of 18 F-FDG images. Collectively, this study show cases the value of a multimodal connectomic, transcriptomic, and pharmacokinetic approach to further investigate dose dependent relationships in preclinical studies, with translational value toward informing clinical study design.

Levetiracetam prevents Aβ42 production through SV2a-dependent modulation of App processing in Alzheimer's disease models

A Randomized Controlled Trial Measuring Changes in Cerebral Blood Flow after Levetiracetam in Patients with Alzheimer’s Disease

Targeting hippocampal amyloidogenesis with SV2A protein modulator levetiracetam

Lamotrigine Attenuates Deficits in Synaptic Plasticity and Accumulation of Amyloid Plaques in App/Ps1 Transgenic Mice

Levetiracetam inhibits oligomeric Aβ-induced glutamate release from human astrocytes

Antiepileptics topiramate and levetiracetam alleviate behavioral deficits and reduce neuropathology in APPswe/PS1dE9 transgenic mice.

Levetiracetam modulates brain metabolic networks and transcriptomic signatures in the 5XFAD mouse model of Alzheimer's disease

A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam

Valproic Acid Inhibits Aβ Production, Neuritic Plaque Formation, and Behavioral Deficits in Alzheimer's Disease Mouse Models

Levistolide A Attenuates Alzheimer's Pathology Through Activation of the PPARγ Pathway

Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer’s Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein

The Synaptic Vesicle Protein 2a Interacts with Key Pathogenic Factors in Alzheimer’s Disease: Implications for Treatment

Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer’s disease mouse model

Simvastatin Prevents Β-Amyloid25–35-impaired Neurogenesis in Hippocampal Dentate Gyrus Through Α7nachr-Dependent Cascading PI3K-Akt and Increasing BDNF Via Reduction of Farnesyl Pyrophosphate

Inhibition of Amyloid-Beta Production, Associated Neuroinflammation, and Histone Deacetylase 2-Mediated Epigenetic Modifications Prevent Neuropathology in Alzheimer’s Disease in vitro Model

Macromolecular and small-molecule modulation of intracellular Aβ42 aggregation and associated toxicity.

Selective suppression of oligodendrocyte-derived amyloid beta rescues neuronal dysfunction in Alzheimer's disease

Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase‐3β Signaling Pathway in an Alzheimer's Disease Model

The cell-permeable Aβ1-6A2VTAT(D) peptide reverts synaptopathy induced by Aβ1-42wt

Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

Deletion of serine racemase reverses neuronal insulin signaling inhibition by amyloid-beta oligomers